Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Intestinal TG3- and TG2-Specific Plasma Cell Responses in Dermatitis Herpetiformis Patients Undergoing a Gluten Challenge.

Sankari H, Hietikko M, Kurppa K, Kaukinen K, Mansikka E, Huhtala H, Laurila K, Reunala T, Hervonen K, Salmi T, Lindfors K.

Nutrients. 2020 Feb 13;12(2). pii: E467. doi: 10.3390/nu12020467.

2.

Gluten Challenge Induces Skin and Small Bowel Relapse in Long-Term Gluten-Free Diet-Treated Dermatitis Herpetiformis.

Mansikka E, Hervonen K, Kaukinen K, Ilus T, Oksanen P, Lindfors K, Laurila K, Hietikko M, Taavela J, Jernman J, Saavalainen P, Reunala T, Salmi T.

J Invest Dermatol. 2019 Oct;139(10):2108-2114. doi: 10.1016/j.jid.2019.03.1150. Epub 2019 Apr 15.

3.

Small-intestinal TG2-specific plasma cells at different stages of coeliac disease.

Hietikko M, Koskinen O, Kurppa K, Laurila K, Saavalainen P, Salmi T, Ilus T, Huhtala H, Kaukinen K, Lindfors K.

BMC Immunol. 2018 Dec 6;19(1):36. doi: 10.1186/s12865-018-0275-7.

4.

Ex vivo Culture of Duodenal Biopsies from Patients with Dermatitis Herpetiformis Indicates that Transglutaminase 3 Antibody Production Occurs in the Gut.

Hietikko M, Hervonen K, Ilus T, Salmi T, Huhtala H, Laurila K, Rauhavirta T, Reunala T, Kaukinen K, Lindfors K.

Acta Derm Venereol. 2018 Mar 13;98(3):366-372. doi: 10.2340/00015555-2849.

5.

Transglutaminase 2 and Transglutaminase 2 Autoantibodies in Celiac Disease: a Review.

Rauhavirta T, Hietikko M, Salmi T, Lindfors K.

Clin Rev Allergy Immunol. 2019 Aug;57(1):23-38. doi: 10.1007/s12016-016-8557-4. Review.

PMID:
27263022
6.

Current status of drugs in development for celiac disease.

Kurppa K, Hietikko M, Sulic AM, Kaukinen K, Lindfors K.

Expert Opin Investig Drugs. 2014 Aug;23(8):1079-91. doi: 10.1517/13543784.2014.916274. Epub 2014 May 7. Review.

PMID:
24806736

Supplemental Content

Loading ...
Support Center